Romano Brothers AND Company Acquires New Stake in Integra LifeSciences Holdings Co. (NASDAQ:IART)

Romano Brothers AND Company bought a new position in Integra LifeSciences Holdings Co. (NASDAQ:IART) in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 8,980 shares of the life sciences company’s stock, valued at approximately $204,000.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in IART. KBC Group NV grew its stake in shares of Integra LifeSciences by 65.2% in the 3rd quarter. KBC Group NV now owns 2,839 shares of the life sciences company’s stock worth $52,000 after purchasing an additional 1,120 shares during the last quarter. Northwest Investment Counselors LLC acquired a new position in Integra LifeSciences in the third quarter worth approximately $73,000. Canada Pension Plan Investment Board bought a new position in shares of Integra LifeSciences in the second quarter valued at $114,000. Centiva Capital LP acquired a new stake in shares of Integra LifeSciences during the 3rd quarter valued at $192,000. Finally, Dynamic Technology Lab Private Ltd bought a new stake in shares of Integra LifeSciences during the 3rd quarter worth $198,000. 84.78% of the stock is owned by institutional investors.

Integra LifeSciences Stock Up 3.7 %

IART stock opened at $24.10 on Monday. The company has a 50 day moving average of $23.20 and a two-hundred day moving average of $22.41. The company has a quick ratio of 0.73, a current ratio of 1.20 and a debt-to-equity ratio of 0.79. Integra LifeSciences Holdings Co. has a 12-month low of $16.81 and a 12-month high of $45.42. The company has a market cap of $1.86 billion, a price-to-earnings ratio of -267.75, a PEG ratio of 0.73 and a beta of 1.16.

Integra LifeSciences (NASDAQ:IART) last released its quarterly earnings data on Monday, November 4th. The life sciences company reported $0.41 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.39 by $0.02. Integra LifeSciences had a positive return on equity of 12.35% and a negative net margin of 0.42%. The firm had revenue of $380.80 million during the quarter, compared to analysts’ expectations of $375.81 million. During the same quarter last year, the firm earned $0.76 earnings per share. The business’s revenue for the quarter was down .4% on a year-over-year basis. On average, equities analysts anticipate that Integra LifeSciences Holdings Co. will post 2.45 earnings per share for the current fiscal year.

Insider Activity at Integra LifeSciences

In other Integra LifeSciences news, EVP Michael J. Mcbreen sold 1,700 shares of Integra LifeSciences stock in a transaction that occurred on Monday, December 2nd. The shares were sold at an average price of $24.16, for a total value of $41,072.00. Following the completion of the sale, the executive vice president now directly owns 56,182 shares in the company, valued at $1,357,357.12. The trade was a 2.94 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 3.10% of the stock is currently owned by company insiders.

Analyst Ratings Changes

Several equities research analysts have recently commented on the company. Bank of America reduced their target price on Integra LifeSciences from $26.00 to $18.00 and set an “underperform” rating for the company in a report on Monday, October 7th. Citigroup upped their price objective on shares of Integra LifeSciences from $16.00 to $22.00 and gave the company a “sell” rating in a research note on Tuesday, November 5th. Morgan Stanley began coverage on shares of Integra LifeSciences in a research report on Monday, December 2nd. They issued an “underweight” rating and a $20.00 target price on the stock. BTIG Research upgraded shares of Integra LifeSciences from a “sell” rating to a “neutral” rating in a research report on Monday, October 7th. Finally, Truist Financial lowered their price objective on shares of Integra LifeSciences from $26.00 to $21.00 and set a “hold” rating on the stock in a research report on Monday, October 14th. Three investment analysts have rated the stock with a sell rating, five have given a hold rating and one has given a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $23.00.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.